Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03401853
Title Rituximab and Pembrolizumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Washington
Indications

follicular lymphoma

relapsed/refractory diffuse large B-cell lymphoma

Therapies

Pembrolizumab + Rituximab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.